Sandu Pharmaceuticals reports ₹78.52 lakh Q2 FY27 profit

Sandu Pharmaceuticals Limited reported profit after tax of ₹0.79 crore for the quarter ended September 30, 2026, on total income of ₹19.52 crore. The unaudited standalone Q2 FY27 results, approved by the Board on November 14, 2026, also showed quarterly expenses of ₹18.66 crore.

What did Sandu Pharmaceuticals report for Q2 FY27?

Sandu Pharmaceuticals reported a standalone profit after tax of ₹0.79 crore in Q2 FY27. The reporting period covered the three months ended September 30, 2026, and the result was released after the company’s Board of Directors considered and approved the financial statements on November 14, 2026.

Total income for the quarter was ₹19.52 crore, while total expenses were ₹18.66 crore. The difference between income and expenses was reflected in the reported profit after tax. The company described the figures as unaudited standalone financial results prepared under Indian Accounting Standards, or Ind-AS.

The result announcement is relevant for shareholders because it provides the company’s financial position for the second quarter of FY27. Sandu Pharmaceuticals is listed on the BSE under scrip code 524703, and the filing relates specifically to its standalone operations.

What were the key financial figures for the September quarter?

The key Q2 FY27 figures were ₹19.52 crore of total income, ₹18.66 crore of total expenses and ₹0.79 crore of profit after tax. All absolute figures have been converted from the reported lakh denomination into crore for a consistent presentation.

The company reported that its half-year profit after tax was ₹1.01 crore. For the six months ended September 30, 2026, total income stood at ₹35.92 crore and total expenses were ₹34.70 crore.

The source material describes the quarterly profit as an increase compared with earlier periods, but it does not provide comparable prior-period profit figures within the detailed financial disclosure. Therefore, the reported release supports the current-period numbers but does not allow a precise year-on-year or sequential growth calculation.

How were Sandu Pharmaceuticals’ Q2 FY27 results approved?

Sandu Pharmaceuticals’ Board of Directors approved the unaudited standalone results at its meeting held on Saturday, November 14, 2026. The Board meeting had been scheduled to consider the company’s financial results for the quarter and half year ended September 30, 2026.

Before the results, the company had informed the market that the meeting would take place at 4:00 PM at its corporate office in Chembur, Mumbai. The notice stated that the agenda covered approval of standalone unaudited results, with no dividend or other corporate action cited in that intimation.

The company’s trading window for directors, officers and designated employees had remained closed from October 1, 2026 until 48 hours after the public announcement of the results. Such restrictions are part of the company’s insider-trading compliance process around price-sensitive financial disclosures.

What review and accounting standards apply to the results?

The Q2 FY27 results were prepared in compliance with Ind-AS and subjected to a limited review by M/s Dave & Dave Chartered Accountants, Mumbai. A limited review is an external review of interim financial information and differs from a full statutory audit of annual accounts.

Sandu Pharmaceuticals also stated that figures for earlier periods were regrouped or reclassified where necessary. This is a standard financial-reporting disclosure intended to maintain comparability when the presentation or classification of line items changes.

The company noted that certain audited quarterly figures are balancing figures between full-year audited results and published year-to-date figures for the respective six-month period. Investors assessing the release should distinguish the current unaudited standalone quarter from audited annual financial statements.

How do the Q2 results matter for investors and operations?

The Q2 filing gives investors a current view of Sandu Pharmaceuticals’ income, cost base and profitability for the September quarter. With total expenses of ₹18.66 crore against income of ₹19.52 crore, operational costs remain a central factor in understanding the company’s reported ₹0.79 crore profit after tax.

The half-year figures provide a broader view of performance across the first six months of FY27. Income of ₹35.92 crore and profit after tax of ₹1.01 crore indicate that the September-quarter result formed a substantial part of the half-year profit reported by the company.

The available disclosure does not provide product-wise sales, segment performance, margins, cash flows, management guidance or a dividend decision. As a result, the release establishes the reported financial outcome but does not provide evidence for conclusions about demand trends, future earnings or changes in business strategy.

Conclusion

Sandu Pharmaceuticals reported a Q2 FY27 standalone profit after tax of ₹0.79 crore, supported by quarterly total income of ₹19.52 crore and expenses of ₹18.66 crore. For the first half of FY27, the company recorded total income of ₹35.92 crore and profit after tax of ₹1.01 crore, with the statements prepared under Ind-AS and reviewed by an external chartered accountant firm.

Investors can watch for the company’s next financial disclosure for further information on revenue trends, expenses and profitability. The present filing identifies the September 30, 2026 quarter and half-year results, but it does not disclose forward targets, business guidance, a dividend decision or other planned corporate actions.